193208-23-0Relevant academic research and scientific papers
Pharmacologic evaluation of antidepressant activity and synthesis of 2-morpholino-5-phenyl-6H-1,3,4-thiadiazine hydrobromide
Sarapultsev, Alexey P.,Chupakhin, Oleg N.,Sarapultsev, Petr A.,Sidorova, Larisa P.,Tseitler, Tatiana A.
, (2016)
Substituted thiadiazines exert a reliable therapeutic effect in treating stress, and a schematic description of their ability to influence all aspects of a stress response has been depicted. This study was conducted to pharmacologically evaluate compound L-17, a substituted thiadiazine, (2-morpholino-5-phenyl-6H-1,3,4-thiadiazine, hydrobromide) for possible anti-psychotic/antidepressant activity. Compound L-17 was synthesized by cyclocondensation of α-bromoacetophenone with the original morpholine-4-carbothionic acid hydrazide. Pharmacologic evaluations were conducted using methods described by E.F. Lavretskaya (1985), and in accordance with published guidelines for studying drugs for neuroleptic activity. Compound L-17 was evaluated for various possible mechanisms of action, including its effects on cholinergic system agonists/antagonists, dopaminergic neurotransmission, the adrenergic system, and 5-HT3 serotonin receptors. One or more of these mechanisms may be responsible for the beneficial effects shown by thiadiazine compounds in experiments conducted to evaluate their activity in models of acute stress and acute myocardial infarction.
Substituted 6H-1,3,4-thiadiazine-2-amines, the use thereof as anaesthetising, cardiovascular and hypometabolic agents, and pharmaceutical composition containing them
-
, (2008/06/13)
Substitued 6H-1,3,4-thiadiazin-2-amines of the following general formula: wherein Ar is phenyl optionally substituted with one or more chloro, bromo atoms, C1-C4alkoxy, or C1-C4alkyl groups; and represents a morpholino, thimomorpholino, piperidino, pyrrolidino, or hexamethylenimino moieties, the pharmaceutically acceptable salts thereof and the use of them anasethetic, cardiovascular and hypometabolic agents and pharmaceutical compositions containing them.
